The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2)
Open accessAbstract
Aims/hypothesis The objective of this prevention programme was to study whether combining pioglitazone with lifestyle modification would enhance the efficacy of lifestyle modification in preventing type 2 diabetes in Asian Indians with impaired glucose tolerance.Methods In a community-based, placebo-controlled 3 year prospective study, 407 participants with impaired glucose tolerance (mean age 45.3 +/- 6.2 years, mean BMI 25.9 +/- 3.3 kg/m(2)) were sequentially grouped to receive either: lifestyle modification plus pioglitazone, 30 mg (n = 204) or lifestyle modification plus placebo (n = 203). The participants and investigators were blinded to the assignment. The primary outcome was development of diabetes.Results At baseline, both groups had similar demographic, anthropometric and biochemical characteristics. At year 3, the response rate was 90.2%. The cumulative incidence of diabetes was 29.8% with pioglitazone and 31.6% with placebo (unadjusted HR 1.084 [95% CI 0.753-1.560], p = 0.665). Normoglycaemia was achieved in 40.9% and 32.3% of participants receiving pioglitazone and placebo, respectively (p = 0.109). In pioglitazone group, two deaths and two non-fatal hospitalisations occurred due to cardiac problems; in the placebo group there were two occurrences of cardiac disease.Conclusions/interpretation Despite good adherence to lifestyle modification and drug therapy, no additional effect of pioglitazone was seen above that achieved with placebo. The effectiveness of the intervention in both groups was comparable with that of lifestyle modification alone, as reported from the Indian Diabetes Prevention Programme-1. The results are at variance with studies that showed significant relative risk reduction in conversion to diabetes with pioglitazone in Americans with IGT. An ethnicity-related difference in the action of pioglitazone in non-diabetic participants may be one explanation.Trial registration ClinicalTrials.gov NCT00276497 FUNDING: This study was funded by the India Diabetes Research Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the Indian DPP-2 study no difference in the rate of diabetes development was found between lifestyle intervention alone and lifestyle intervention plus pioglitazone during a 3-year trial.100”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Self-citationThe Finnish Diabetes Prevention Study (DPS)
Lindström, J., Louheranta, A., Mannelin, M., Rastas, M., Salminen, V., Eriksson, J., Uusitupa, M., Tuomilehto, J., & for the Finnish Diabetes Prevention Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3230 · Cited by 1,848
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males
Kosaka, K., Noda, M., & Kuzuya, T. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.06.010 · Cited by 656
Research works printed but not linked: 1
- World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus WHO/NCD/NCS/99.2. World Health Organization, Geneva
Cited by
Sorted by citations
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationPrediabetes diagnosis and treatment: A review
Bansal, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i2.296 · Cited by 579
Diagnosis and Management of Prediabetes: A Review
Echouffo-Tcheugui, J. B., Perreault, L., Ji, L., & Dagogo-Jack, S. (2023) · JAMA · doi:10.1001/jama.2023.4063 · Cited by 473
Prediabetes and what it means: the epidemiological evidence
Echouffo-Tcheugui, J. B., & Selvin, E. (2021) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-090419-102644 · Cited by 406
Metadata
- Authors
- Ramachandran, A., Snehalatha, C., Mary, S., Selvam, S., Kumar, C. K. S., Seeli, A. C., & Shetty, A. S.
- Affiliations
- India Diabetes Research Foundation (IN)
- Corresponding author
- Ramachandran, A.
- ORCID
- Ramachandran, A.
- Venue
- Diabetologia
- Published
- 2009-03-10
- Volume
- 52
- Issue
- 6
- Pages
- 1019-1026
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1968039145
- Cited by
- 105
- References
- 24
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 13 · 2023: 6 · 2022: 5 · 2021: 5 · 2020: 9 · 2019: 2 · 2018: 11 · 2017: 3 · 2016: 7 · 2015: 6 · 2014: 6 · 2013: 3 · 2012: 7
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Emory University
- India Diabetes Research Foundation
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- pioglitazone, impaired glucose tolerance, type 2 diabetes prevention, lifestyle modification, Asian Indians, ethnic differences in drug response, PPARγ agonists, adverse cardiac events
- MeSH terms
- Pioglitazone, Adult, Combined Modality Therapy, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Life Style, Male, Middle Aged, Models, Theoretical, Prospective Studies, Glucose Intolerance, Asian People, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
